Skip to Content

Carlos E. Bueso-Ramos, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Hematopathology and Section Chief of Diagnostic Bone Marrow, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 Emory University School of Medicine, Atlanta, GA, PHD, Experimental Pathology
1982 Universidad Autonoma, Tegucigalpa, Honduras, MD, Medicine

Postgraduate Training

1/1999-12/1999 Management in the changing world of health care, Rice University Graduate School of Management, Houston, TX
7/1992-6/1994 Hematopathology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1991-6/1992 Surgical Pathology/Hematopathology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1987-6/1991 Pathology Residency Training Program (AP/CP), Emory University School of Medicine, Atlanta, GA

Board Certifications

6/1995 Hematopathology, American Board of Pathology
6/1992 Anatomic and Clinical Pathology, American Board of Pathology

Honors and Awards

2013-2014 Waun Ki Hong Award, Excellence in Team Science, UT M. D. Anderson Cancer Center
2013-2014 WHO's WHO

Selected Publications

Peer-Reviewed Original Research Articles

1. Zhou Y, Kanagal-Shamanna R, Zuo Z, Tang G, Medeiors LJ, Bueso-Ramos CE. Advances in B-lymphoblastic leukemia: Cytogenetic and genomic lesions. Annals of Diagnostic Pathology 16(S1092-9134):30019-30023, 8/2016. PMID: 27130145.
2. Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. Multiparameter analysis of off-target effects of Dasatinib on bone homeostasis in patients with newly diagnosed chronic myelogenous leukemia. Clinical Lymphoma, Myeloma & Leukemia(16 Suppl):S86-92, 8/2016. PMID: 27521332.
3. Gallardo M, Hornbaker MJ, Zhang X, Hu P, Bueso-Ramos C, Post SM. Aberrant hnRNP K expression: All roads lead to cancer. Cell Cycle. e-Pub 4/2016. PMID: 27049467.
4. Takahashi K, Patel K, Bueso-Ramos C, Zhang J Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-14187, 3/2016. PMID: 26871476.
5. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7(12):14251-14258, 2/2016. PMID: 26883102.
6. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell 28(4):486-99, 10/12/2015. e-Pub 9/24/2015. PMCID: PMC4652598.
7. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 9/4/2015. PMID: 26343946.
8. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol 90(9):769-73, 9/2015. e-Pub 7/27/2015. PMCID: PMC4546505.
9. Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol 144(3):377-92, 9/2015. PMID: 26276769.
10. Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, Hanson CA. Therapy-Related Myeloid Neoplasms. Am J Clin Pathol 144(2):207-218, 8/2015. PMID: 26185306.
11. Bueso Ramos CE, Medeiros LJ, Vega-Vazquez F. Introduction to the 2013 Workshop of the Society for Hematopathology/European Association for Haematopathology. Am J Clin Pathol 144(1):4-5, 7/2015. PMID: 26071457.
12. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 5/11/2015. PMCID: PMC4596059.
13. Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol 169(3):344-51, 5/2015. e-Pub 1/22/2015. PMID: 25612675.
14. Zuo Z, Maiti S, Hu S, Loghavi S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper LJ, Bueso-Ramos CE. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetially normal myelodysplastic syndromes. Mod Pathol 28(3):373-82, 3/2015. e-Pub 9/12/2014. PMID: 25216221.
15. Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw 13(1):19-22, 1/2015. PMID: 25583766.
16. Tang G, DiNardo C, Zhang L, Ravandi F, Khoury JD, Huh YO, Muzzafar T, Medeiros LJ, Wang SA, Bueso-Ramos CE. MLL gene amplification in acute myeloid leukemia and myelodysplasti syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. Hum Pathol 46(1):S0046-8177(14)00374-8, 1/2015. e-Pub 10/2/2014. PMID: 25387813.
17. Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. J Natl Cancer Inst 108(2), 2015. e-Pub 11/13/2015. PMID: 26568194.
18. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280-8, 6/2014. e-Pub 11/25/2013. PMCID: PMC4032802.
19. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE, Konopleva M, Andreeff M. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kB mediates chemoresistance. Blood 123(17):2691-2702, 4/2014. PMID: 24599548.
20. Chakhachiro ZI, Zuo Z, Aladily TN, Kantarjian HM, Cortes JE, Alayed K, Nguyen MH, Medeiros LJ, Bueso-Ramos C. CD105 (Endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. AJCP 140(3), 9/2013. PMID: 23955456.
21. Heinrichs S*, Conover L, Bueso-Ramos C, Kilpivaara O. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife, 7/2013. PMCID: PMCPMC3713455.
22. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer. e-Pub 6/17/2013. PMID: 23775587.

Last updated: 8/30/2016